Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO WCGIC 2020 | PANGEA: personalized antibodies for gastroesophageal adenocarcinoma

Daniel Catenacci, MD, of the University of Chicago, Chicago, IL, discusses the phase IIa PANGEA study (NCT02213289), a precision medicine trial in gastroesophageal adenocarcinoma, evaluating biomarkers for antibody therapy. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).